1. Introduction {#sec1-ijerph-17-03395}
===============

Multimorbidity, commonly defined as the cooccurrence of two or more chronic diseases, has gained increasing attention as a prominent public health issue worldwide \[[@B1-ijerph-17-03395]\]. Multimorbidity has been associated with poorer health outcomes including greater risk of disability and mortality among older populations \[[@B2-ijerph-17-03395]\]. Additionally, it complicates treatment and health care plans and increases the risk of psychiatric and somatic complications, thus leading to higher healthcare expenditures and resource utilization \[[@B3-ijerph-17-03395],[@B4-ijerph-17-03395]\].

A large body of literature has reported multimorbidity prevalence and patterns worldwide. It was reported that the prevalence of multimorbidity ranged from 45% to 72% among older adults aged 50 years and over in nine countries \[[@B5-ijerph-17-03395]\] and ranged from 24% to 83% among those aged 60 years and older in South Asia \[[@B6-ijerph-17-03395]\]. In addition, the overall prevalence of multimorbidity among older adults is widely ranged from 6.4% to 86.9% in China \[[@B7-ijerph-17-03395]\]. Additionally, studies have observed different multimorbidity patterns, such as cardiometabolic patterns, mental health patterns, and musculoskeletal patterns, using cluster analysis, factor analysis, or Association rule mining (ARM) \[[@B8-ijerph-17-03395],[@B9-ijerph-17-03395],[@B10-ijerph-17-03395]\]. Nevertheless, multimorbidity patterns are expected to have unique characteristics for different countries because of a variance in factors such as environment, race/ethnicity, and lifestyles \[[@B11-ijerph-17-03395]\].

However, most research studies investigating multimorbidity in China have been conducted among community-dwelling populations and defined chronic conditions using self-reported questionnaires or face-to-face interviews, which can be affected by recall and selection bias \[[@B8-ijerph-17-03395],[@B9-ijerph-17-03395],[@B12-ijerph-17-03395],[@B13-ijerph-17-03395],[@B14-ijerph-17-03395]\]. The population-based estimates derived from claims data were very limited, especially in Asian countries \[[@B14-ijerph-17-03395],[@B15-ijerph-17-03395],[@B16-ijerph-17-03395]\]. Studies based on claims data defined multimorbidity using more objective clinical diagnoses without recall/non-response bias based on a patient-based population \[[@B17-ijerph-17-03395],[@B18-ijerph-17-03395]\]. Furthermore, using International Classification of Diseases (ICD) codes in claims data also facilitated the international comparability of understanding multimorbidity \[[@B19-ijerph-17-03395]\].

In addition, current multimorbidity studies have mostly focused on older adults aged ≥60 years \[[@B20-ijerph-17-03395],[@B21-ijerph-17-03395],[@B22-ijerph-17-03395],[@B23-ijerph-17-03395]\]. One recent study reported that multimorbidity had a greater impact on all-cause mortality in middle-aged populations than in older populations \[[@B24-ijerph-17-03395]\]. There was found to be a greater hospitalization burden among middle-aged people with multimorbidity than their older counterparts as well \[[@B25-ijerph-17-03395]\]. Middle-aged patients with multimorbidity represent a vulnerable group with distinct chronic care needs \[[@B25-ijerph-17-03395]\]. Studies on multimorbidity among middle-aged adults are therefore essential to address their need for personalized health care.

Better understanding of multimorbidity prevalence and patterns among different populations can help explore possible interactions between different diseases as well as improve population-specific approaches for managing multimorbidity to lessen the public health burden \[[@B26-ijerph-17-03395],[@B27-ijerph-17-03395]\]. This study therefore aimed to evaluate the prevalence and patterns of multimorbidity (i.e., combinations and clustering of chronic diseases) among middle-aged and older Chinese adults using claims data accumulated through a mandatory insurance programme in Beijing, China.

2. Materials and Methods {#sec2-ijerph-17-03395}
========================

2.1. Data Source {#sec2dot1-ijerph-17-03395}
----------------

This study used data from the Beijing Medical Claim Data for Employees (BMCDE), a mandatory health insurance programme consisting of all working and retired workers in Beijing \[[@B28-ijerph-17-03395],[@B29-ijerph-17-03395]\]. BMCDE included information on patients' demographic characteristics (age and sex), inpatient and outpatient clinical diagnoses, and medications, with personal identifiers removed. All clinical visits of patients could be linked with their unique encrypted identification number. This study was considered exempt because BMCDE data were collected for administrative purposes with personal identifiers removed for research purposes.

2.2. Measurement of Multimorbidity and Study Population {#sec2dot2-ijerph-17-03395}
-------------------------------------------------------

For this study, the following thirteen chronic diseases were selected based on the most frequently mentioned diseases for multimorbidity measures by previous literatures that were considered to significantly impact long-term treatment and decrease functional performance and quality of life among the Chinese population \[[@B30-ijerph-17-03395],[@B31-ijerph-17-03395]\]: malignancy, cerebrovascular disease (CBD), ischaemic heart disease (IHD), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), depressive disorders (DD), chronic kidney disease (CKD), osteoarthritis and rheumatoid arthritis (OARA), peptic ulcer disease (PUD), cataracts, heart failure (HF), hypertension (HT), and glaucoma. Diseases were identified if they had been documented using inpatient or outpatient ICD-10 codes at least twice in individual medical records during the 5-year period from January 1, 2011 to December 31, 2015 \[[@B32-ijerph-17-03395],[@B33-ijerph-17-03395]\]. For this study, a total of 2,097,150 people aged ≥45 years in 2015 were included. [Table S1](#app1-ijerph-17-03395){ref-type="app"} lists all chronic medical diseases included and their corresponding ICD-10 codes. For this study, multimorbidity was defined as concurrently suffering from two or more chronic diseases.

2.3. Statistical Analyses {#sec2dot3-ijerph-17-03395}
-------------------------

Age was categorized into the following two subgroups: 45--59 years (middle-aged group) and ≥60 years (older group). Continuous variables were examined using the mean (standard deviation, SD). Categorical variables were summarized with frequencies (percentages), and the *X*^2^ test was performed to compare these characteristics. Given the sufficiently large sample size in this study, all tests showed a significant p value (*p* \< 0.001), which is not presented in the results \[[@B34-ijerph-17-03395]\].

ARM was applied to determine common multimorbidity patterns that met a minimum requirement of measurement indicators among large sets of diagnoses. Association rules were relationships between sets of diseases from "antecedent" to "consequent" \[[@B35-ijerph-17-03395]\]. The following are the three common measurement indicators in ARM: support (the frequency of the disease combinations in the association rule), confidence (how frequently the antecedent diseases occur, conditional on the consequent diseases), and lift (how much more frequently the diseases set in the same association rule occur together compared with the expected prevalence under statistical independence). Lift was considered the main measure of significance in ARM \[[@B36-ijerph-17-03395]\]. The higher the lift, the higher the chance of co-occurrence of the consequent with the antecedent and the more significant the association \[[@B36-ijerph-17-03395]\]. For this study, the minimum thresholds of parameters in ARM were defined as follows: support \> 2%, confidence \> 10%, and lift \> 1%. Hierarchical cluster analysis (HCA) was used to identify those diseases that were inclined to gather together according to their correlated structure and similarity patterns. Those that were strongly correlated or had similar diseases were classified into the same clusters using homogeneity criteria \[[@B37-ijerph-17-03395]\]. The homogeneity criterion of a cluster is defined as the sum of correlation ratios \[[@B37-ijerph-17-03395]\]. The function "hclustvar" in the R package "ClustOfVar" was used in the clustering analysis ([www.r-project.org](www.r-project.org)). All analyses were performed using R 3.2.2 (R Development Core Team).

3. Results {#sec3-ijerph-17-03395}
==========

[Table 1](#ijerph-17-03395-t001){ref-type="table"} shows the basic demographics and prevalence of chronic diseases in the studied population. This study included 2,097,150 people aged ≥45 years, with 50.0% (*n* = 1,048,575) aged 45--59 years (middle-aged group) and 50.0% (*n* = 1,048,575) aged ≥60 years (older group). The mean age was 52.8 years for those aged 45--59 years and 70.3 years for those aged ≥60 years.

[Figure 1](#ijerph-17-03395-f001){ref-type="fig"} shows the multimorbidity prevalence by age and sex. The prevalence of multimorbidity was 51.6% (male: 46.1%; female: 55.7%) in the middle-aged group and 81.3% (male: 78.8%; female: 83.7%) in the older group. The overall proportion of people with multimorbidity increased from 51.6% for those aged 45--59 years to 89.3% for those over 90 years. Females had a higher prevalence than males for each age group.

The most frequent (top 3) combinations, stratified by age, sex, and total number of chronic diseases, are presented in [Table 2](#ijerph-17-03395-t002){ref-type="table"}. Among patients with at least two chronic conditions, OARA combined with HT was the most prevalent disease pair for patients of all ages (male: 29.6%; female: 37.6%), male middle-aged patients (male: 16.0%; female: 27.3%), and male older patients (35.1%). Among older females, IHD combined with OARA was the most prevalent disease pair (49.2%). Furthermore, IHD, HT, and OARA was the most common triad combination among patients with at least three chronic conditions (middle-aged male: 8.0%; middle-aged female: 13.2%; older male: 26.4%; older female: 36.6%).

The ARM results illustrated the associations between these diseases. The top 10 association rules among the included diseases according to lift are shown in [Table 3](#ijerph-17-03395-t003){ref-type="table"}. Among the middle-aged patients, the strongest association was found between the combination of CBD, OARA, HT, and IHD in males where the lift was 3.49, whereas the highest lift for females was 3.24 for the combination of CBD, OARA, COPD, and IHD, making these diseases occur together with 3.49- or 3.24-times higher likelihoods, respectively, than would be expected if they were independent. Among older adults, the strongest associations were observed between glaucoma and cataracts in females (lift = 2.952) and the combination of IHD, OARA, and glaucoma with cataracts in males (lift = 2.450), indicating that these antecedent combinations positively correlated with the occurrence of cataracts. Moreover, in the middle-aged group, IHD tended to be comorbid with others that occurred in 9 association rules in males and 10 in females among the top 10 rules. In contrast, among the older males, cataracts and diabetes were the most common comorbidities, and both occurred in 5 association rules.

Disease clusters derived from HCA stratified by age and sex are shown in [Figure 2](#ijerph-17-03395-f002){ref-type="fig"}a--d. Common disease clusters observed in the four subgroups included a visual impairment cluster consisting of glaucoma and cataract and a mixed cluster of OARA, IHD, and COPD. Furthermore, a cardiometabolic cluster, including HF, HT, DM and CKD, was detected among middle-aged female individuals and the older group.

4. Discussion {#sec4-ijerph-17-03395}
=============

To the best of our knowledge, this study was among the first to explore multimorbidity prevalence and patterns based on large medical claims data among a middle-aged and older Chinese population. The prevalence of multimorbidity increased with age. Females had a higher prevalence of multimorbidity than males. OARA, combined with HT, was the most prevalent disease pair for patients of all ages. IHD, HT, and OARA was the most common triad combination. In addition, several disease clusters were identified in our study including a visual impairment cluster, a mixed cluster of OARA, IHD, and COPD, and a cardiometabolic cluster. There were strong associations between CBD, OARA, and IHD among the middle-aged group and between glaucoma and cataracts among the older group.

We found that the prevalence of multimorbidity was 51.6% for middle-aged adults aged 45--59 and 81.3% for older adults aged ≥60 years. One study using claims data from Taiwan in 2013 showed a similar prevalence of multimorbidity, which was 56.8%, 74.6%, and 82.6% in people aged 60--69, 70--79, and 80--89 years, respectively \[[@B16-ijerph-17-03395]\]. Additionally, two European studies based on claims data also reported that the multimorbidity prevalence among adults aged ≥60 years old was 85% in Germany \[[@B14-ijerph-17-03395]\] and 77% in Switzerland \[[@B15-ijerph-17-03395]\]. Consistent with previous studies, we observed a higher prevalence of multimorbidity among females than among males, which may be partially due to the relatively higher prevalence of select chronic diseases in females \[[@B8-ijerph-17-03395],[@B38-ijerph-17-03395],[@B39-ijerph-17-03395],[@B40-ijerph-17-03395]\]. One study conducted in six low- and middle-income countries among adults aged ≥50 years reported a higher overall prevalence of six chronic diseases, including angina, arthritis, asthma, chronic lung disease, depression, and HT, in females \[[@B41-ijerph-17-03395]\]. Moreover, the incidence of chronic inflammatory diseases in females after menopausal age, as a result of hormonal changes, exceeded that observed in males \[[@B42-ijerph-17-03395]\]. One alternative explanation might be that females were generally more aware of their own health status and had more healthcare-seeking behaviours, which might lead to a higher probability of being diagnosed with diseases \[[@B43-ijerph-17-03395]\].

According to the frequency, we found that the most prevalent disease pair was OARA combined with HT, and the most common triad combination was IHD, HT, and OARA. A multi-country study reported similar results: comorbid diseases of HT and arthritis were highly prevalent in China, Finland, Ghana, Poland, Russia, South Africa, and Spain \[[@B5-ijerph-17-03395]\]. A study in Belgium also detected the most prevalent pair as HT-OA \[[@B44-ijerph-17-03395]\]. Moreover, the lift in ARM discovered interesting combinations of comorbidities that were occurring more frequently than expected. In our study, the ranked lift indicated that there were strong associations between vascular and musculoskeletal disorders, including CBD, IHD, and HT with OARA. A cross-sectional study conducted in Europe observed that HT was one of the most common comorbidities among individuals with osteoarthritis (OA) \[[@B45-ijerph-17-03395]\]. In addition, a meta-analysis showed that there was a significant relationship between cardiovascular disease (CVD) and OA \[[@B46-ijerph-17-03395],[@B47-ijerph-17-03395]\]. Possible explanations for the relationship between CVD and OARA include shared biological mechanisms, such as ageing and obesity \[[@B48-ijerph-17-03395],[@B49-ijerph-17-03395],[@B50-ijerph-17-03395]\]. For example, obesity can induce chronic inflammation and endothelial dysfunction, which are simultaneously implicated in cartilage degradation, atherosclerosis, and a higher CVD risk \[[@B51-ijerph-17-03395]\]. Overweight and obese people also have reduced levels of physical activity and functional limitations, which are concomitant risk factors for CVD, joint pain and OARA \[[@B52-ijerph-17-03395]\]. Moreover, individuals with nonsteroidal anti-inflammatory medication treatments could contribute substantially to the OA--CVD association \[[@B53-ijerph-17-03395]\]. The observations of prevalent disease combinations could have implications for health prevention, where measurements targeting a specific factor may benefit two or more related diseases.

Furthermore, strong associations between IHD, OARA, and COPD were also detected by ARM and HCA. Our findings were consistent with those from a study using medical record data in Sweden which reported significantly associated comorbidities, including IHD and OA, among COPD patients \[[@B54-ijerph-17-03395]\]. Similarly, a population-based cohort in Canada also observed COPD and HT as prevalent comorbidities among people with OA \[[@B55-ijerph-17-03395]\]. Moreover, a systematic review confirmed that the prevalence of OA was high among individuals with COPD \[[@B56-ijerph-17-03395]\]. The potential mechanisms might include increased systemic inflammatory mediators and some adverse effects, such as physical inactivity, which are also risk factors for other diseases \[[@B56-ijerph-17-03395]\]. Compared to a study conducted in rural China, it observed the most prevalent multimorbidity pattern for CBD, HT, and DM, which might be attributed to an imbalance in the delivery of primary care services, such as the lack of blood pressure and blood glucose monitoring, and availability of essential medicines in rural districts \[[@B57-ijerph-17-03395]\]. Moreover, in older females, strong associations between IHD, OARA, glaucoma, and cataracts were observed, partially owing to the high prevalence of these diseases \[[@B58-ijerph-17-03395]\]. The ARM results also reported common comorbidities, including IHD among middle-aged individuals and DM in males. Survival bias may explain the age and gender difference for the comorbidity, as IHD and DM were linked to higher mortality in older \[[@B59-ijerph-17-03395]\] and female \[[@B60-ijerph-17-03395]\] patients, respectively.

The main strength of this study was the large sample size of the administrative data used to illustrate multimorbidity prevalence and patterns among a middle-aged and older Chinese population. The multimorbidity measures defined by the ICD codes, including a broad range of chronic diseases, can help detect specific patterns potentially left out in survey-based studies. This study also had several limitations. First, the BMCDE database only included people who had been employed, leading to limited generalizability to a general population. Additionally, although claims data included ICD-10 codes recorded by well-trained doctors in certified hospitals, we could not necessarily ensure exclusion of inaccurate or underreporting diagnoses. Finally, the dataset did not include patients' socioeconomic status, anthropometric parameters, detailed clinical information, as well as health-related behaviours. We therefore could not investigate potential confounding factors and take disease severity into consideration.

5. Conclusions {#sec5-ijerph-17-03395}
==============

Multimorbidity was prevalent among middle-aged and older Chinese individuals. Females had a higher prevalence than males. The most prevalent disease pair was OARA combined with HT. The most common triad combination consisted of IHD, HT, and OARA. CVDs (including CBD, IHD, and HT), OARA and COPD were more likely to co-occur. The observations of the multimorbidity pattern, including the most frequent comorbidities, associations, and clusters in our study, provide evidence for the priority of disease clusters for further research and encourage healthcare providers to develop healthcare plans towards a multiple-condition framework among patients with multimorbidity. Deep understanding of the complexity of multimorbidity based on large administrative datasets can improve the quality and efficiency of patient-centred care.

The following are available online at <https://www.mdpi.com/1660-4601/17/10/3395/s1>, Table S1: The ICD-10 codes for the select diseases included.
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Dendrograms of cluster analysis showing the distribution and aggregation of chronic diseases in (**a**) middle-aged males, (**b**) middle-aged females, (**c**) older males, and (**d**) older females.
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###### 

Observed prevalence of chronic diseases by age and sex.

                                        45 ≤ Age ≤ 59    Age ≥ 60                                                            
  ------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Age (yrs), mean (SD)**              52.8 (4.3)       52.7 (4.3)       52.9 (4.2)       70.3 (8.0)       70.5 (8.1)       70.0 (8.0)
  **Chronic health disease, *n* (%)**                                                                                        
  **Malignancy**                        58,077 (5.5)     28,112 (6.3)     29,965 (5.0)     94,008 (9.0)     44,195 (8.7)     49,813 (9.2)
  **CBD**                               81,777 (7.8)     39,936 (8.9)     41,841 (6.9)     263,451 (25.1)   138,135 (27.2)   125,316 (23.2)
  **IHD**                               231,483 (22.1)   112,274 (25.1)   119,209 (19.8)   587,596 (56.0)   273,645 (53.8)   313,951 (58.2)
  **COPD**                              206,724 (19.7)   100,081 (22.4)   106,643 (17.7)   394,699 (37.6)   181,243 (35.6)   213,456 (39.5)
  **DM**                                216,014 (20.6)   104,721 (23.5)   111,293 (18.5)   317,576 (30.3)   163,205 (32.1)   154,371 (28.6)
  **DD**                                113,530 (10.8)   55,000 (12.3)    58,530 (9.7)     128,534 (12.3)   51,017 (10.0)    77,517 (14.4)
  **CKD**                               57,640 (5.5)     27,944 (6.3)     29,696 (4.9)     130,281 (12.4)   66,252 (13.0)    64,029 (11.9)
  **OARA**                              467,787 (44.6)   226,943 (50.8)   240,844 (40.0)   707,436 (67.5)   306,174 (60.2)   410,262 (74.3)
  **PUD**                               125,720 (12.0)   61,089 (13.7)    64,631 (10.7)    190,506 (18.2)   89,638 (17.6)    100,868 (18.7)
  **Cataract**                          37,363 (3.6)     18,151 (4.1)     19,212 (3.2)     216,475 (20.6)   88,028 (17.3)    128,447 (23.8)
  **HF**                                10,835 (1.0)     5280 (1.2)       5555 (0.9)       48,672 (4.6)     24,717 (4.9)     23,955 (4.4)
  **HT**                                520,324 (49.6)   252,602 (56.6)   267,722 (44.5)   681,179 (65.0)   335,584 (66.0)   345,595 (64.0)
  **Glaucoma**                          23,188 (2.2)     11,212 (2.5)     11,976 (2.0)     51,695 (4.9)     21,195 (4.2)     30,500 (5.6)

Abbreviations: SD, standard deviation; CBD, cerebrovascular disease; IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DD, depressive disorders; CKD, chronic kidney disease; OARA, osteoarthritis and rheumatoid arthritis; PUD, peptic ulcer disease; HF, heart failure; HT, hypertension.

ijerph-17-03395-t002_Table 2

###### 

Top three frequent unique combination clusters for patients with multimorbidity, stratified by total number of chronic diseases and by sex.

  Age Group                                                  Rank   Dyads of Morbidities   Triads of Morbidities                                                                                           
  ---------------------------------------------------------- ------ ---------------------- ----------------------- ------------- ---------------- ------------------- ---------------- ------------------- ----------------
  All ages; male: *n* = 955,257, female: *n* = 1,141,893                                                                                                                                                   
                                                             1      OARA + HT              282,995 (29.6)          OARA + HT     429,553 (37.6)   IHD + OARA + HT     194,735 (20.4)   IHD + OARA + HT     276,928 (24.3)
                                                             2      IHD + HT               272,230 (28.5)          IHD + OARA    383,889 (33.6)   COPD + OARA + HT    132,923 (13.9)   COPD + OARA + HT    204,352 (17.9)
                                                             3      IHD + OARA             255,872 (26.8)          IHD + HT      324,411 (28.4)   IHD + COPD + OARA   130,557 (13.7)   IHD + COPD + OARA   198,311 (17.4)
  45--59 years; male: *n* = 446,540, female: *n* = 602,035                                                                                                                                                 
                                                             1      OARA + HT              71,626 (16.0)           OARA + HT     164,234 (27.3)   IHD + OARA + HT     35,719 (8.0)     IHD + OARA + HT     79,290 (13.2)
                                                             2      DM + HT                65,518 (14.7)           COPD + OARA   120,912 (20.1)   DM + OARA + HT      24,719 (5.5)     COPD + OARA + HT    70,249 (11.7)
                                                             3      IHD + HT               63,979 (14.3)           IHD + OARA    118,355 (19.7)   COPD + OARA + HT    24,367 (5.5)     IHD + COPD + OARA   58,021 (9.6)
  ≥60 years; male: *n* = 602,035, female: *n* = 539,858                                                                                                                                                    
                                                             1      OARA + HT              211,369 (35.1)          IHD + OARA    265,534 (49.2)   IHD + OARA + HT     159,016 (26.4)   IHD + OARA + HT     197,638 (36.6)
                                                             2      IHD + HT               208,251 (34.6)          OARA + HT     265,319 (49.1)   IHD + COPD + OARA   110,904 (18.4)   IHD + COPD + OARA   140,290 (26.0)
                                                             3      IHD + OARA             206,397 (34.3)          IHD + HT      230,795 (42.8)   COPD + OARA + HT    108,556 (18.0)   COPD + OARA + HT    134,103 (24.8)

Abbreviations: IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; OARA, osteoarthritis and rheumatoid arthritis; HT, hypertension.

ijerph-17-03395-t003_Table 3

###### 

The top 10 association rules in the order of lift.

  Middle-Aged        Older                                                                                                                                      
  ------------------ ------- ------- ------------------------ ----- ------- ----------------------- ---------- ------- ----------------------------- ---------- -------
  CBD + OARA + HT    IHD     3.487   CBD + OARA + COPD        IHD   3.237   IHD + OARA + Glaucoma   Cataract   2.450   Glaucoma                      Cataract   2.952
  CBD + OARA         IHD     3.321   CBD + COPD               IHD   3.169   IHD + Glaucoma          Cataract   2.419   OARA + PUD + CKD              COPD       2.008
  OARA + HT + PUD    IHD     3.020   CBD + OARA + HT          IHD   3.134   HT + Glaucoma           Cataract   2.417   IHD + DD + OARA + HT          IHD        2.006
  COPD + OARA + HT   IHD     2.981   CBD + OARA               IHD   2.992   OARA + Glaucoma         Cataract   2.382   IHD + COPD + DD               IHD        1.997
  DM + OARA + HT     IHD     2.945   CBD + HT                 IHD   2.874   Glaucoma                Cataract   2.311   IHD + CKD + PUD               COPD       1.992
  COPD + DM          IHD     2.781   COPD + DM + OARA + HT    IHD   2.821   CBD + CKD + HT          DM         2.062   CKD + PUD + HT                COPD       1.961
  COPD + HT          IHD     2.692   COPD + PUD + OARA + HT   IHD   2.764   IHD + CKD + HT          DM         1.953   IHD + DM + OARA + PUD + HT    IHD        1.957
  PUD + HT           IHD     2.637   COPD + DM + HT           IHD   2.736   CBD + IHD + CKD         DM         1.946   CBD + IHD + CKD + OARA + HT   COPD       1.956
  COPD + PUD         OARA    2.623   COPD + PUD + HT          IHD   2.711   IHD + CKD + OARA + HT   DM         1.937   IHD + DD + HT                 IHD        1.952
  CBD + HT           IHD     2.593   CBD                      IHD   2.692   CBD + CKD               DM         1.933   CKD + OARA + Cataract         COPD       1.945

Abbreviations: CBD, cerebrovascular disease; IHD, ischaemic heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DD, depressive disorders; CKD, chronic kidney disease; OARA, osteoarthritis and rheumatoid arthritis; PUD, peptic ulcer disease; HT, hypertension.
